198 related articles for article (PubMed ID: 37821454)
1. Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
Harjes S; Kurup HM; Rieffer AE; Bayarjargal M; Filitcheva J; Su Y; Hale TK; Filichev VV; Harjes E; Harris RS; Jameson GB
Nat Commun; 2023 Oct; 14(1):6382. PubMed ID: 37821454
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
Harjes S; Kurup HM; Rieffer AE; Bayaijargal M; Filitcheva J; Su Y; Hale TK; Filichev VV; Harjes E; Harris RS; Jameson GB
bioRxiv; 2023 Feb; ():. PubMed ID: 36824964
[TBL] [Abstract][Full Text] [Related]
3. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
4. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
5. NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity.
Byeon IJ; Ahn J; Mitra M; Byeon CH; Hercík K; Hritz J; Charlton LM; Levin JG; Gronenborn AM
Nat Commun; 2013; 4():1890. PubMed ID: 23695684
[TBL] [Abstract][Full Text] [Related]
6. Creating RNA Specific C-to-U Editase from APOBEC3A by Separation of Its Activities on DNA and RNA Substrates.
Tang G; Xie B; Hong X; Qin H; Wang J; Huang H; Hao P; Li X
ACS Synth Biol; 2021 May; 10(5):1106-1115. PubMed ID: 33938211
[TBL] [Abstract][Full Text] [Related]
7. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
[TBL] [Abstract][Full Text] [Related]
8. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
9. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
10. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
[TBL] [Abstract][Full Text] [Related]
11. Seven-membered ring nucleobases as inhibitors of human cytidine deaminase and APOBEC3A.
Kurup HM; Kvach MV; Harjes S; Jameson GB; Harjes E; Filichev VV
Org Biomol Chem; 2023 Jun; 21(24):5117-5128. PubMed ID: 37282621
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
Sakhtemani R; Senevirathne V; Stewart J; Perera MLW; Pique-Regi R; Lawrence MS; Bhagwat AS
J Biol Chem; 2019 Oct; 294(41):15037-15051. PubMed ID: 31431505
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B.
Shi K; Carpenter MA; Banerjee S; Shaban NM; Kurahashi K; Salamango DJ; McCann JL; Starrett GJ; Duffy JV; Demir Ö; Amaro RE; Harki DA; Harris RS; Aihara H
Nat Struct Mol Biol; 2017 Feb; 24(2):131-139. PubMed ID: 27991903
[TBL] [Abstract][Full Text] [Related]
14. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.
Jalili P; Bowen D; Langenbucher A; Park S; Aguirre K; Corcoran RB; Fleischman AG; Lawrence MS; Zou L; Buisson R
Nat Commun; 2020 Jun; 11(1):2971. PubMed ID: 32532990
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context.
Seplyarskiy VB; Andrianova MA; Bazykin GA
Genome Res; 2017 Feb; 27(2):175-184. PubMed ID: 27940951
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
Buisson R; Lawrence MS; Benes CH; Zou L
Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
[TBL] [Abstract][Full Text] [Related]
17. Stem-loop structure preference for site-specific RNA editing by APOBEC3A and APOBEC3G.
Sharma S; Baysal BE
PeerJ; 2017; 5():e4136. PubMed ID: 29230368
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage.
Wick C; Moghadasi SA; Becker JT; Fanunza E; Oh S; Bournique E; Buisson R; Harris RS
J Biol Chem; 2023 Sep; 299(9):105073. PubMed ID: 37474103
[TBL] [Abstract][Full Text] [Related]
19. Elephant APOBEC3A cytidine deaminase induces massive double-stranded DNA breaks and apoptosis.
Li X; Caval V; Wain-Hobson S; Vartanian JP
Sci Rep; 2019 Jan; 9(1):728. PubMed ID: 30679716
[TBL] [Abstract][Full Text] [Related]
20. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
Naumann JA; Argyris PP; Carpenter MA; Gupta HB; Chen Y; Temiz NA; Zhou Y; Durfee C; Proehl J; Koniar BL; Conticello SG; Largaespada DA; Brown WL; Aihara H; Vogel RI; Harris RS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
